| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Team Building > The Benefits of 2-Way Performance Evaluations |
|
E-Folder - The Benefits of 2-Way Performance Evaluations
As with many ideas I have, I later find that they have already been thought of. This idea is no exception. S According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product overeign Bank handles employee evaluations in a, in my opinion, remarkable way. Not only do supervisors and m ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in nagers evaluation the performance of their respective departments, but their departments evaluate them! Here lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. are some of the benefits I see in this type of 2-way evaluation:
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe any type of department, no matter how happy they seem, team members will bad mouth not only management, but d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ach other. It’s unavoidable. Joe isn’t pulling his weight, Max is a jerk most of the time, or whatever else s ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc omeone can think of to complain about… will be complained about. Opening performance evaluations to the team easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi allows you to uncover these underlying issues in a professional, maybe even friendly, environment where areas nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically for growth can be identified and presented positively. In a team environment and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ many people share in the glory of success and the sting of failure. Typically, however, there are a few indi ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi iduals who really shine in a given project whose contributions may be overshadowed by the team. It’s the resp ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a onsibility of management to stop this from happening, but no matter how vigilant, details will be missed and dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ccomplishments will go overlooked. When the entire team can evaluate each other these accomplishments reach cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin are identified to make sure the team member responsible receives the credit they deserve. tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen irit In many organizations, they “say” they foster spirit of team where everyone is of equal importance t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel n reaching company goals. Yet, how many organizations put their management on a pedestal where they aren’t ev ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust aluated by their department members? Is this really the behavior of a team… or a dictatorship? Allowing team y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products members to evaluate their leaders is essential to growing a sense of team where everyone is equal and no one . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de is of more valuable than the other.
There are other benefits to this type of evaluation, but I b elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip lieve these are the strongest. By breaking down the walls that surround our team, we can build stronger ones tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:On The Road Again...Techniques For Increasing Productivity When You're Traveling A Review Of Opening Statements
|